Related references
Note: Only part of the references are listed.Brachytherapy: Current Status and Future Strategies - Can High Dose Rate Replace Low Dose Rate and External Beam Radiotherapy?
G. C. Morton et al.
CLINICAL ONCOLOGY (2013)
Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity
Gabriella Pietra et al.
CANCER RESEARCH (2012)
Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients
Sergiusz Markowicz et al.
MEDICAL ONCOLOGY (2012)
Tumor Immunotherapy Directed at PD-1
Antoni Ribas
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer
Celestia S. Higano et al.
CANCER (2009)
Regulatory T-Cell - Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma
Theo Nicholaou et al.
CLINICAL CANCER RESEARCH (2009)
Increased Survival From Stage IV Melanoma Associated With Fewer Regulatory T Cells
Joel M. Baumgartner et al.
JOURNAL OF SURGICAL RESEARCH (2009)
Local IL-21 Promotes the Therapeutic Activity of Effector T cells by Decreasing Regulatory T Cells Within the Tumor Microenvironment
Seunghee Kim-Schulze et al.
MOLECULAR THERAPY (2009)
Immune modulation by melanoma-derived factors
Dan Ilkovitch et al.
EXPERIMENTAL DERMATOLOGY (2008)
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 study group
Alessandro Testori et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
A. M. Krieg
ONCOGENE (2008)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients
Barbara G. Molenkamp et al.
CLINICAL CANCER RESEARCH (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
G. Parmiani et al.
ANNALS OF ONCOLOGY (2007)
Tumor-released microvesicles as vehicles of immunosuppression
Roberta Valenti et al.
CANCER RESEARCH (2007)
Tumor exosomes inhibit differentiation of bone marrow dendritic cells
Shaohua Yu et al.
JOURNAL OF IMMUNOLOGY (2007)
Analyses and perspectives in cancer immunotherapy
P. Nguyen van Binh et al.
BIOMEDICINE & PHARMACOTHERAPY (2006)
Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity
R. Kim et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2006)
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro
C Blank et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Defective human leukocyte antigen class I-associated antigen presentation caused by a novel β2-microglobulin loss-of-function in melanoma cells
Chien-Chung Chang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients
A Tuettenberg et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
A Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma
SA Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2005)
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
U Keilholz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immune selection of hot-spot β2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy
CC Chang et al.
JOURNAL OF IMMUNOLOGY (2005)
Toll-like receptors: linking innate and adaptive immunity
C Pasare et al.
MICROBES AND INFECTION (2004)
A review of recent findings involving interleukin-2-based cancer therapy
JW Eklund et al.
CURRENT OPINION IN ONCOLOGY (2004)
Different effects of interferon-α on melanoma cell lines:: a study on telomerase reverse transcriptase, telomerase activity and apoptosis
E Maellaro et al.
BRITISH JOURNAL OF DERMATOLOGY (2003)
Exosomes bearing HLA-G are released by melanoma cells
B Riteau et al.
HUMAN IMMUNOLOGY (2003)
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine
EC Hsueh et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes:: Clinical and immunologic findings
F Belli et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Immunity against cancer: lessons learned from melanoma
AN Houghton et al.
CURRENT OPINION IN IMMUNOLOGY (2001)
Induction of primary NY-ESO-1 immunity:: CD8+T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+cancers
E Jäger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
CE Touloukian et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
